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the CC BY-NC-ND license (http://creaAbstract Objective: Small cell prostate carcinoma (SCPC) is a rare and highly malignant sub-
type of prostate cancer. SCPC frequently lacks androgen receptor (AR) and prostate-specific
antigen (PSA) expression, and often responds poorly to androgen deprivation therapy (ADT).
AR splice variant-7 (AR-V7) is a truncated AR protein implicated in resistance to AR-targeting
therapies. AR-V7 expression in castration-resistant prostate cancers has been evaluated exten-
sively, and blood-based detection of AR-V7 has been associated with lack of response to abir-
aterone and enzalutamide. However, whether AR-V7 is expressed in SCPC is not known.
Methods: Using validated antibodies, we performed immunohistochemistry (IHC) assay for the
full-length AR (AR-FL) and (AR-V7) on post-ADT surgical SCPC specimens.
Results: Seventy-five percent (9/12) of the specimens showed positive staining for the AR-FL
with various intensities. Thirty-three percent (4/12) of the specimens showed positive staining
for AR-V7. Among the specimens with positive AR-V7 staining, two samples displayed very weak
staining, one sample showed weak-to-moderate staining, and one sample showed strong stain-
ing. All positive specimens displayed a heterogeneous pattern of AR-FL/AR-V7 staining. All
specimens positive for AR-V7 were also positive for AR-FL.
Conclusion: The study findings support the existence of measurable AR-FL and AR-V7 proteins
in SCPC specimens. The results also have implications in detection of AR-V7 in specimens ob-
tained through systemic sampling approaches such as circulating tumor cells. A positive AR-V7
finding by blood-based tests is not impossible in patients with SCPC who often demonstrate low
PSA values.
ª 2019 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).oo.com (L. Cheng), jluo1@jhmi.edu (J. Luo).
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Small cell prostate carcinoma (SCPC) is a rare and highly
malignant subtype of prostate cancer. SCPC only accounts
for 0.5%e2% of untreated primary prostate cancer at initial
diagnosis [1,2], but can present in up to 25% metastatic
castration-resistant prostate cancer (CRPC) autopsies [3].
SCPC frequently lacks expression of androgen receptor (AR)
and AR downstream target genes such as prostate-specific
antigen (PSA), and often responds poorly to androgen
deprivation therapy (ADT) [2]. The widespread application
of potent next-generation hormonal therapies such as
enzalutamide and abiraterone may also lead to increased
occurrences of treatment related SCPC [4].
Resistance to ADT in prostate cancer is often associated
with aberrant androgen receptor (AR) activities mediated
by AR protein overexpression, AR gene amplification, mu-
tation and emergence of constitutively active AR variants
such as AR splice variant-7 (AR-V7) [5e7]. However,
detailed expression pattern of different AR isoforms in
primary SCPC patients who received prior ADT remains
poorly characterized. In this study, we have developed and
validated antibodies for immunohistochemistry (IHC) assays
suitable for evaluation of full length AR (AR-FL) and AR-V7
in primary SCPC specimens. The expression of AR-FL and
AR-V7 protein were determined in post-ADT radical pros-
tatectomy (RP) or transurethral resection of the prostate
(TURP) samples from 12 SCPC patients.
2. Materials and methods
2.1. Patients and tissue samples
This research was approved by the Institutional Review
Board (IU IRB 1808872882). SCPC specimens were collected
surgically via RP or TURP. All the patients were previously
treated with hormonal therapy. The patients’ age ranged
from 43 to 87 years old (mean, 70 years). Eleven cases were
from TURP and one from RP (SC-06).
2.2. IHC assays
For AR C-terminus IHC, the antigen retrieval was done by
placing the de-paraffinized slides in Antigen Unmasking
Solution, Tris-Based High pH (H-3301; Vector Lab, Burlin-
game, CA, USA) at 95C for 40 min. The slides were incu-
bated with the rabbit monoclonal anti-human AR C-
terminus antibody (1:200; Sigma-Aldrich, Saint Louis, MO,
USA, catalog number: SAB5500007) for 1 h at room tem-
perature. The secondary antibody was a ready-to-use anti-
rabbit poly HRP IgG (PowerVision, PV6118; Leica Bio-
systems, Buffalo Grove, IL, USA) and was incubated with
the slides for 30 min at room temperature.
For AR-V7 IHC, the antigen retrieval was done by placing
the de-paraffinized slides in Antigen Unmasking Solution,
Tris-Based High pH (H-3301) at 95C for 20 min. The slides
were incubated with the rabbit monoclonal anti-human
AR-V7 antibody (1:200, RevMAb Biosciences, South SanFrancisco, CA, USA, catalog number: 31-1109-00) for
70 min at room temperature. The secondary antibody was a
ready-to-use anti-rabbit poly HRP IgG (PowerVision,
PV6118) and it was incubated with the slides for 30 min at
room temperature.
All the stained slides were scanned by Leica Biosystems
Aperio AT2 Digital Pathology scanner (Leica Biosystems
Imaging, Buffalo Grove, IL, USA) at 40 magnification. The
IHC staining nuclear RGB intensity value was determined by
Aperio ImageScope (Leica Biosystems Imaging, Buffalo
Grove, IL, USA) using algorithm developed by Johns Hopkins
University. The nuclear AR-FL staining intensity was classi-
fied as negative (nuclear RGB intensity value 220e250) and
positive (nuclear RGB intensity value 219). The AR-FL
positive nuclear staining was further classified as weak
(nuclear RGB intensity value 200e219), moderate (nuclear
RGB intensity value 180e199) and strong (nuclear RGB in-
tensity 155e179). The nuclear AR-V7 staining intensity was
classified as negative (nuclear RGB intensity value
220e250) and positive (nuclear RGB intensity value 219).
Positive AR-V7 nuclear staining was further classified as
weak (nuclear RGB intensity value 210e220), moderate
(nuclear RGB intensity value 188e209) and strong (nuclear
RGB intensity value 162e187). The total number of cells
were determined by hematoxylin staining using Aperio
ImageScope (Leica Biosystems Imaging, Vista, CA, USA).
The percentage of positive tumor cells was calculated as
number of cells with positive AR-FL or AR-V7 nuclear
staining divided by total number of cells in the tissue.
Samples were defined as AR-FL or AR-V7 positive if the total
number of AR-FL or AR-V7 positive tumor cells were above
0.5% in the tissue.3. Results
3.1. Validation of AR-FL and AR-V7 IHC assays
The antibodies targeting AR-FL and AR-V7 were validated
using prostate cancer cell lines with known AR profiles.
Both antibodies were tested in LNCaP95 cells, which ex-
press both AR-FL and AR-V7, and the AR-negative PC3 cells
[8]. The Western blot for the AR-V7 antibody (RevMab,
South San Francisco, CA, USA) was examined and demon-
strated in a previous publication from our group [9]. The
Western blot for the AR-C-terminal domain (AR-CTD) anti-
body (Sigma, Saint Louis, MO, USA) only showed a single
specific band for AR-FL as shown in Fig. 1, along with the
IHC results. In LNCaP95 cells, both AR-V7 and AR-FL were
detected predominantly in the nuclei, consistent with the
expected expression pattern in this cell line. The antibodies
showed good specificity to the corresponding antigens given
lack of IHC staining in the AR-negative PC3 cell line.
3.2. AR-FL and AR-V7 protein expression in post-
ADT SCPC cases
Twelve surgical (RP or TURP) SCPC specimens were
collected from patients after neoadjuvant hormonal
Figure 1 Western blot of the full length androgen receptor
(AR-FL) with androgen receptor C-terminal domain (AR-CTD)
antibody and immunohistochemistry (IHC) staining of different
AR isoforms in LNCaP95 and PC3 cell lines.
Detection of AR and AR-V7 in SCPC by IHC 111therapy at Indiana University School of Medicine. The
diagnosis of SCPC was based on 2016 WHO classification
system [10]. Seventy-five percent (9/12) of the speci-
mens showed positive AR-FL nuclear staining with varying
intensities. Thirty-three percent (4/12) of the specimens
showed positive nuclear staining for AR-V7. The summary
of the staining results is shown in Table 1. The quantifi-
cation of the staining was achieved by using Aperio
ImageScope (Leica Biosystems Imaging, Vista, CA, USA)
and the algorithm was developed by Johns Hopkins
University.
Among the four specimens with positive AR-V7 staining,
two samples (SC-03 and SC-04) displayed very weak stain-
ing, one sample (SC-02) showed weak-to-moderate stain-
ing, and one sample (SC-01) showed strong staining. All
positive specimens displayed a heterogeneous pattern ofTable 1 Positive staining percentage of AR-V7 and AR-CTD
IHC for 12 SCPC tissue specimens.
Case AR-V7 AR CTD
SC-01 49.9% 73.9%
SC-02 7.0% 88.3%
SC-03 0.8% 56.6%
SC-04 2.6% 55.9%
SC-05 Negative 59.1%
SC-06 Negative 92.0%
SC-07 Negative 31.1%
SC-08 Negative 41.7%
SC-09 Negative 10.7%
SC-10 Negative Negative
SC-11 Negative Negative
SC-12 Negative Negative
AR-V7, androgen receptor splice variant-7; IHC, immunohisto-
chemistry; AR-CTD, androgen receptor C-terminal domain;
SCPC, small cell prostate carcinoma.AR/AR-V7 staining. All specimens positive for AR-V7 were
also positive for the AR-FL. Sample staining results of AR-V7
and AR-CTD are shown in Fig. 2.
4. Discussion
SCPC is one of the most lethal forms of prostate cancer. It
has usually metastasized at initial diagnosis, and would not
respond to hormonal therapy. Cisplatin or doxorubicin-
based chemotherapies are the main treatment, and the
median overall survival of SCPC is significantly shorter
compared to usual adenocarcinoma. In general, SCPC does
not express prostate cancer specific markers such as AR and
PSA. However, recent studies suggested SCPC may also
express detectable level of AR and AR targeted genes [11].
In a recent xenograft study, a fraction of AR-positive
enzalutamide-resistant tumors carried neuroendocrine
features, indicating an AR-indifferent status [12]. This
finding indicate that SCPC, especially those that arise after
treatments, may continue to express AR-FL and AR-V7. AR-
FL is detected in a substantial proportion of SCPC speci-
mens. It is currently unknown why detection of AR-FL do
not confer response to AR-targeting therapies (e.g., enza-
lutamide or abiraterone) in SCPC patients. It is possible that
although some SCPC cells remains AR-FL positive, they may
become “AR-indifferent” [13].
Our study is limited by the small sample size (n Z 12).
However, the purpose of the study was to evaluate AR-Figure 2 Representative images of the immunohistochem-
istry staining (IHC) for androgen receptor C-terminal domain
(AR-CTD) and androgen receptor splice variant-7 (AR-V7). (A)
AR-CTD IHC for SC-01 (100 magnification); (B) AR-V7 IHC for
SC-01 (100 magnification); (C) AR-CTD IHC for SC-01; (D) AR-
V7 IHC for SC-01.
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an AR-V7 antibody that had been extensively validated in
a recent study using CRPC specimens [9]. The current
study generated a few notable observations. First, this is
the first study establishing AR-V7 protein can be detected
in SCPC specimens using a validated antibody. Second,
the heterogeneous pattern of AR-FL/AR-V7 expression
indicates that AR-FL/AR-V7 positive cells may coexist
with AR negative cells in SCPC, possibly reflecting a
transition state from an AR-driven disease to AR-
indifferent or AR-independent disease. Third, consistent
with results from non-SCPC CRPC specimens, we did not
observe cells that were AR-V7 positive but AR-FL nega-
tive, further supporting the conclusion that AR-V7 always
coexists with AR-FL [14]. The results are informative and
have important implications. Blood-based AR-V7 tests
have been implemented for clinical use [15e17]. Testing
platform included the PCR-based test developed at our
institution, and IHC-based test developed by EPIC Bio-
sciences. AR-V7 positive cells presenting heterogeneous
expression pattern may be detected by both test plat-
forms. As such, positive results may be found in some
patients with SCPC, even though such patients may pre-
sent low serum PSA values. Therefore, some patients
with low PSA but positive AR-V7 may be evaluated for the
presence of SCPC, a diagnostic entity that may mandate
metastatic biopsies.
5. Conclusion
The study demonstrated AR-FL/AR-V7 expression in a sub-
stantial fraction of treatment related SCPC specimens. The
functional and clinical relevance of AR/AR-V7 detection in
this setting remains unknown. This finding, however, may
help to interpret liquid biopsy-based detection of AR-V7 in
patients with low PSA. Future investigation will focus on
clinical correlation in an expanded patient cohort.
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